Priority Lists
Protocol Posting of
Activations
Activation Notice
Phase II Evaluation Of Neoadjuvant Chemotherapy, Interval Debulking Followed By Intraperitoneal Chemotherapy In Women With Stage III And IV Epithelial Ovarian Cancer, Fallopian Tube Cancer Or Primary Peritoneal Cancer
| Study Coordinator(s) | Amy D. Tiersten, M.D., Harriet O. Smith, M.D., Sharon Wilczynski, M.D.,Ph.D. |
| Participants | Members, NCORP, Surgeons |
Phase II Trial of Concurrent Cisplatin/Docetaxel and Radiotherapy Followed by Consolidation Docetaxel in Stage IIIB Non-Small Cell Lung Cancer
| Study Coordinator(s) | Raja Mudad, M.D., FACP, Laurie E. Gaspar, M.D., R. Chapman, M.D. |
| Participants | Members, NCORP, Medical Oncologists, Radiation Oncologists |
Closures
Permanent Closure
A Phase II Study of Daunomycin and Ara-C Given by Continuous IV Infusion with PSC-833 for Previously Untreated Non-M3 Acute Myeloid Leukemia (AML) in Patients of Age 56 or Older
| Study Coordinator(s) | Thomas R. Chauncey, M.D.,Ph.D., John E. Godwin, M.D., Alan F. List, M.D., David R. Head, M.D., Cheryl L. Willman, M.D., Jacqueline R. Batanian, Ph.D. |
| Participants | Pathologists, NCORP, Members |
| Closure Date | 2001-03-15 |
Amendments, Revisions, Memoranda
SWOG Revision #1 regarding GOG Revsion #6. New procedure for SWOG patient registration. GOG Form T included.
A Randomized Phase III Trial of IV Carboplatin (AUC 6) and Paclitaxel 175 mg/m2 Q 21 Days X 3 Courses Plus Low Dose Paclitaxel 40 mg/m2/wk Versus IV Carboplatin (AUC 6) and Paclitaxel 175 mg/m2 Q 21 Days X 3 Courses Plus Observation in Patients With Early Stage Ovarian Carcinoma.
| Study Coordinator(s) | Carolyn M. Johnston, M.D. |
| Participants | Members, NCORP |
MEMORANDUM
A Phase III Randomized Double Blind Study of Letrozole Versus Placebo in Women With Primary Breast Cancer Completing Five or More Years of Adjuvant Tamoxifen
| Study Coordinator(s) | Silvana Martino, D.O. |
Revision #2
A Phase I Study of Tirapazamine/Cisplatin/Etoposide and Concurrent Thoracic Radiotherapy for Limited Stage Small Cell Lung Cancer
| Study Coordinator(s) | Quynh-Thu X. Le, M.D., Stephen K. Williamson, M.D., Janice Ryu, M.D. |
| Participants | Members, NCORP, Medical Oncologists, Radiation Oncologists |
Memo regarding tissue processing and patient billing.
Evaluation of In Vitro Assays as Predictors of Clinical Outcome in Patients With Locally Advanced (Stage IIB-IVA)Cervical Carcinoma, Biologic
| Study Coordinator(s) | Robert A. Burger, M.D., Bradley J. Monk, M.D., Sharon Wilczynski, M.D.,Ph.D., Robert S. Lavey, M.D.,Ph.D. |
| Participants | Members, NCORP, Medical Oncologists, Radiation Oncologists, Surgeons, Pathologists |
Revision #2
A Randomized Phase III Trial of ICE Chemotherapy With or Without Rituximab for the Treatment of Relapsed or Refractory CD20 Expressing Agressive B-Cell Non-Hodgkin's Lymphomas in Patients Not Suitable for High Dose Therapy and PBSCT.
| Study Coordinator(s) | David G. Maloney, M.D.,Ph.D., Thomas P. Miller, M.D., Thomas M. Grogan, M.D. |
| Participants | Members, NCORP, Medical Oncologists, Pathologists |
Revision #4
Evaluation of the Combination of Docetaxel (Taxotere®)/ Carboplatin in Patients with Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck (SCCHN), Phase II
| Study Coordinator(s) | Wolfram E. Samlowski, M.D., J. Philip Kuebler, M.D.,Ph.D. |
| Participants | Members, Medical Oncologists, NCORP |
Revision #4
A Phase III Trial of Dexamethasone, Cyclophosphamide, Etoposide, Cisplatin (DCEP) and G-CSF With or Without Thalidomide (NSC #66847) as Salvage Therapy for Patients with Refractory Multiple Myeloma
| Study Coordinator(s) | Mohamad A. Hussein, M.D., James K. Weick, M.D. |
| Participants | NCORP, Members |
Other New Items
- IP - Pts Must Be Informed
- AC - Consent Must Be Amended
- CBR - No Registration Allowed until IRB Review
- RC - Formal Re-consent Required
- FBR - Full Board Review Required
- ER - Expedited Review Acceptable
- NR - No IRB Review Required